Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

NCT07635342 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

182

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Pyrotinib Maleate
DRUG: Trastuzumab (H, 8mg/kg
DRUG: pegylated liposomal doxorubicin hydrochloride
DRUG: Cyclophosphamide
DRUG: Paclitaxel for Injection Albumin Bound

Sponsor

Hebei Medical University Fourth Hospital